Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1375-1381

  Iqbal, Tariq ^a   Stein, Jürgen ^b   Sharma, Naveen ^c   Kulnigg Dabsch, Stefanie ^d   Vel, Senthil ^e   Gasche, Christoph ^d  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b Crohn Colitis Center Rhein Main   (Germany)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Vifor (International) Inc   (Switzerland)

Author keywords

Anemia; C reactive protein; Crohn s disease; Inflammatory bowel disease; Iron deficiency; Iron therapy; Ulcerative colitis

Indexed keywords

ANTIANEMIC AGENT; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRIC CARBOXYMALTOSE; FERRIC ION; FERROUS ION; FERROUS SULFATE; HEMOGLOBIN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MALTOSE;

ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; BLOOD; COLITIS, ULCERATIVE; COMPARATIVE STUDY; CROHN DISEASE; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; C-REACTIVE PROTEIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALTOSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939936304     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3460-4     Document Type: Article

References (29)

1. Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299–1307.
2. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.
3. Gasche C, Berstad A, Befrits R, Beglinger C, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.
4. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1507–1523.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023.
6. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093.
7. Vermeire S, Van AG, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.
8. Kindmark CO. The concentration of C-reactive protein in sera from healthy individuals. Scand J Clin Lab Invest. 1972;29:407–411.
9. Van Assche G, Dignass A, Bokemeyer B, Danese S, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1–33.
10. Wiesenthal M, Dignass A, Hartmann F, Iqbal T, Stein J. Serum hepcidin levels predict intestinal iron absorption in IBD patients. J Crohns Colitis. 2014;8:S120.
11. Semrin G, Fishman DS, Bousvaros A, Zholudev A, et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006;12:1101–1106.
12. Wiesenthal M, Dignass A, Hartmann F, Stein J. The type of iron deficiency anaemia, but not the underlying disease, predicts intestinal iron absorption in IBD patients. J Crohns Colitis. 2014;8:S195–S196.
13. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol. 2003;38:543–548.
14. de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22:1097–1105.
15. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182–1192.
16. Evstatiev R, Gasche C. Iron sensing and signalling. Gut. 2012;61:933–952.
17. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood. 1989;74:844–851.
18. Sharma N, Laftah AH, Brookes MJ, Cooper B, Iqbal T, Tselepis C. A role for tumour necrosis factor alpha in human small bowel iron transport. Biochem J. 2005;390:437–446.
19. Laftah AH, Sharma N, Brookes MJ, McKie AT, et al. Tumour necrosis factor alpha causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J. 2006;397:61–67.
20. Sharma N, Begum J, Eksteen B, Elagib A, et al. Differential ferritin expression is associated with iron deficiency in coeliac disease. Eur J Gastroenterol Hepatol. 2009;21:794–804.
21. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013;88:97–101.
22. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:1681–1689.
23. Ward DG, Roberts K, Stonelake P, Goon P, et al. SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Sci. 2008;6:28.
24. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol. 2012;23:1954–1962.
25. Gasche C, Waldhoer T, Feichtenschlager T, Male C, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382–2387.
26. Schroder O, Mickisch O, Seidler U, de WA, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005; 100:2503–2509.
27. Lindgren S, Wikman O, Befrits R, Blom H, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44:838–845.
28. Reinisch W, Staun M, Tandon RK, Altorjay I, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877–1888.
29. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology. 1993;104:1285–1292.